Tomáš Büchler - Concepedia

Author

Tomáš Büchler

Also Known As

Buchler T, J. Prausova, Jana Hornova, Jana Prausova, Jiri Tomasek, Ladislav Jarolim, T Buchler, T Büchler, T. BUCHLER, T. Buchler

405

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Charles University Thomayer University Hospital Masaryk University Masaryk Memorial Cancer Institute Palacký University Olomouc

About

Tomáš Büchler is an author at Charles University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	49	2K
2	Health Sciences	8	8	746
3	Engineering	2	2	50
4	Public Health	2	2	48
5	Allergy	2	2	39

Tomáš Büchler

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer Thomas Powles, James W.F. Catto, Matthew D. Galsky, New England Journal of Medicine	2024	245
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, The Lancet Oncology Pembrolizumab Versus SunitinibUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2023	149
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study Alexandr Poprach, Tomáš Pavlík, Bohuslav Melichar, Annals of Oncology UrologySkin CancerNational Registry-based StudyGenitourinary CancerMedicine	2012	112
Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease Marta Krejčí, Michael Doubek, Tomáš Büchler, Annals of Hematology Mycophenolate MofetilTransplantationXenotransplantationMedicineTissue Transplantation	2005	83
Single Nucleotide Polymorphisms within Interferon Signaling Pathway Genes Are Associated with Colorectal Cancer Susceptibility and Survival Shun Lu, Barbara Pardini, Bowang Cheng, PLoS ONE Seven SnpsOncologyColorectal Cancer SusceptibilityMedicineGenetics	2014	76
Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy Pavel Němec, Zuzana Zemanová, Henrieta Grešlíková, Biology of Blood and Marrow Transplantation	2009	70
Cancer Incidence and Mortality in the Czech Republic Ladislav Dušek, Denisa Malúšková, Ondřej Májek, Klinicka onkologie	2014	69
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry Tomáš Büchler, Radim Klapka, Bohuslav Melichar, Annals of Oncology UrologyCzech RegistryGenitourinary CancerMedicineMetronomic Therapy	2011	69

Page 1